Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 69Recurrence 20Neoplasms, Plasma Cell 6Neoplasms 4Lymphoma 3Small Cell Lung Carcinoma 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Kidney Failure, Chronic 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Neoplasms 1Blast Crisis 1

Interventions

peginesatide 1orellanine 1hematide 1carfilzomib 1belantamab mafodotin 1Sitagliptin Phosphate 1Duration of Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Failure, Chronic × carfilzomib × Clear all
NCT01949532 2017-05-02

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

Amgen

Phase 1 Completed
26 enrolled 41 charts
GenitourinaryPlasma cell

Kidney Failure, Chronic, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡